David Drake
Family Medicine · Oakhurst, CANPI 1205941481
Payments from drug & device makers
Across 137 payments — averaging $16.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$364
- Pfizer$309
- AbbVie$161
- Bayer$156
- Astellas Pharma US Inc$125
- Lilly USA, LLC$119
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,312100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 22 | $364 |
| Pfizer | 22 | $309 |
| AbbVie(2 entities) | 10 | $161 |
| Bayer | 4 | $156 |
| Astellas Pharma US Inc | 7 | $125 |
| Lilly USA, LLC | 8 | $119 |
| Insmed, Inc. | 3 | $107 |
| Sunovion Pharmaceuticals Inc. | 10 | $104 |
| Novo Nordisk | 6 | $100 |
| Novartis | 5 | $88 |
| Scilex Pharmaceuticals Inc. | 4 | $80 |
| Amgen | 4 | $72 |
| Amarin Pharma, Inc. | 4 | $64 |
| Ferring Pharmaceuticals Inc. | 3 | $62 |
| Esperion Therapeutics, Inc. | 3 | $62 |
| Merck | 4 | $53 |
| Avanir Pharmaceuticals, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $34 |
| Si-bone, Inc. | 1 | $24 |
| Organon | 1 | $24 |
| IBSA Pharma Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
| Sanofi Pasteur Inc. | 1 | $11 |
How this compares
$2,312 in reported general payments places this provider in the 80th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 58 | $517 |
| Diclofenac Sodium | 17 | $399 |
| Azithromycin | 98 | $302 |
| CefuroximeCefuroxime Axetil | 15 | $269 |
| Cefdinir | 21 | $226 |
| SsdSilver Sulfadiazine | 19 | $116 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 14 | $105 |
| Tobramycin | 12 | $80 |
| Meloxicam | 32 | $57 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $48 |
| Amoxicillin | 11 | $25 |
| Prednisone | 15 | $11 |
| PaxlovidNirmatrelvir/Ritonavir | 26 | $0 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPaxlovid | $309 | $026 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,533 family medicine providers in California.
Other family medicine in Oakhurst
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.